文献速递慢性静脉疾病

直接口服抗凝药与抗血小板治疗下静脉支架置入结局的单中心回顾性分析

Outcomes of endovascular venous stenting in patients on direct oral anticoagulants and antiplatelet therapy at a tertiary referral center.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-08-20

DOAC组55例可分析患者12个月一期、一期辅助和二期辅助通畅率分别为87%、97%和98%,非DOAC组分别为87%、93%和95%。结论认为DOAC治疗下的一期通畅率可接受。

要点

  • DOAC组12个月一期通畅率为87%,与非DOAC组相同。
  • DOAC组一期辅助和二期辅助通畅率分别为97%和98%。
  • 非DOAC组12个月一期、一期辅助和二期辅助通畅率分别为87%、93%和95%。

核心结论

  • 单中心回顾性分析显示,使用DOAC治疗的患者一期通畅率与使用华法林或低分子肝素者相比可接受。

研究设计与样本

  • 回顾性分析2014年1月1日至2018年4月30日连续100例因髂腔或髂股静脉梗阻接受腔内支架置入的患者。
  • 识别使用DOAC、华法林或低分子肝素(LMWH)伴或不伴抗血小板治疗的患者。
  • DOAC组平均随访14个月(范围1-43个月),32例(58%)随访≥12个月。

主要发现

  • DOAC组12个月一期、一期辅助和二期辅助通畅率分别为87%、97%和98%。
  • 非DOAC组12个月一期、一期辅助和二期辅助通畅率分别为87%、93%和95%。
  • DOAC组55例中53例使用抗血小板治疗(氯吡格雷、阿司匹林或两者);非DOAC组19例中18例使用抗血小板治疗。

临床怎么用

  • 对于接受腔内静脉支架置入的患者,DOAC可作为术后抗凝选择之一,其12个月一期通畅率与华法林或LMWH相当。
  • 多数患者同时接受了抗血小板治疗,但本研究未评估抗血小板治疗对通畅率的独立影响。

局限性

  • 单中心回顾性设计,样本量有限(DOAC组仅55例可分析)。
  • DOAC组失访率较高(23%)。
  • 随访时间较短,平均14个月,仅58%患者随访≥12个月。
  • 非DOAC组样本量小(19例),组间比较未报告统计学检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovenous revascularization is the standard in the management of acute thrombotic, chronic post-thrombotic iliocaval or iliofemoral obstruction, and nonthrombotic iliac vein lesions. The purpose of this study is to describe our single-center experience of postprocedure anticoagulation and antiplatelet regimens used after endovenous revascularization for a variety of venous occlusive conditions. METHODS: We conducted a retrospective analysis of 100 consecutive patients who underwent endovenous stenting for iliocaval or iliofemoral obstruction from January 1, 2014, to April 30, 2018. Patients treated with direct oral anticoagulants, warfarin, or low-molecular-weight heparin (LMWH) with or without antiplatelet therapy were identified. Demographic, procedural, patency, and follow-up data were collected. Stent patency was evaluated using duplex Doppler ultrasound examination or contrast venography. RESULTS: Seventy-one of 100 patients were treated with direct oral anticoagulant therapy (DOAC). Sixteen (23%) were lost to follow-up, leaving 55 (77%) available for analysis. The mean follow-up was 14 months (range, 1-43 months) with 32 patients (58%) followed for 12 months or longer. Primary, primary-assisted, and secondary-assisted patency rates were 87%, 97%, and 98%, respectively, at 12 months. In the non-DOAC group (patients treated with warfarin or LMWH), these rates were 87%, 93%, and 95%, respectively, at 12 months. Antiplatelet therapy, including clopidogrel, aspirin, or both, was used in 53 of 55 patients in the DOAC cohort and 18 of 19 patients in the non-DOAC group. CONCLUSIONS: Our-single center retrospective analysis demonstrates acceptable primary patency rates when using DOAC therapy compared with those treated with warfarin or LMWH.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Hays K, Jolly M, Silver M, et al. Outcomes of endovascular venous stenting in patients on direct oral anticoagulants and antiplatelet therapy at a tertiary referral center. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32827732. doi:10.1016/j.jvsv.2020.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。